Description: Description: EC5026 (BPN19186) is a novel, first-in-class, potent and orally bioabailable inhibitor of soluble Epoxide Hydrolase (sEH). EC5026 has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators.
References: EicOsis
Announces FDA Acceptance of IND Application for EC5026, the First
Soluble Epoxide Hydrolase Inhibitor to Treat Pain.2019.